List view / Grid view

head and neck squamous cell carcinoma (HNSCC)

Filter the results

 

news

FDA approves Merck’s head and neck cancer drug

8 August 2016 | By Merck

Under the FDA’s accelerated approval regulations, Keytruda, a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells, is approved based on tumour response rate and durability of response. However, continued approval for the drug may be contingent upon…

news

Merck releases new data for Keytruda at ASCO

6 June 2016 | By Victoria White, Digital Content Producer

Keytruda is a humanised monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells...